Referred to the House Committee on Energy and Commerce.
The Prevent Halting of Active Research Act of 2025 (PHARA) requires the Department of Health and Human Services, through the NIH Director, to immediately release and expend funds required by existing NIH grant or cooperative agreements, pay pending reimbursements, and not cancel agreements under which awardees are performing active, ongoing research. For new NIH grants and cooperative agreements after enactment, the bill requires inclusion of a termination clause limiting termination to cases of material breach, change in circumstances, or mutual agreement, and imposes a 90-day written notice plus a required attempt to amend before termination.
Progressives emphasize protections for research continuity and guarding against political interference; conservatives emphasize restriction of agency discretion and taxpayer oversight.
Relative to its intended legislative type, this bill establishes clear substantive legal obligations on NIH and HHS regarding release of funds, limits on termination authority, mandatory contract clause content, and a specific regulatory revision.
The Prevent Halting of Active Research Act of 2025 (PHARA) requires the Department of Health and Human Services, through the NIH Director, to immediately release and expend funds required by existing NIH grant or cooperative agreements, pay pending reimbursements, and not cancel agreements under which awardees are performing active, ongoing research.
For new NIH grants and cooperative agreements after enactment, the bill requires inclusion of a termination clause limiting termination to cases of material breach, change in circumstances, or mutual agreement, and imposes a 90-day written notice plus a required attempt to amend before termination.
The bill also prohibits NIH from terminating grants or cooperative agreements on the basis that the award no longer effectuates program goals or agency priorities, and directs HHS/NIH to revise 2 C.F.R. §200.340(a) to conform to that prohibition.
On content alone, the bill is narrowly tailored and administratively focused, which helps its prospects. However, it materially constrains NIH termination authority and directs immediate release of funds for existing agreements—actions that could draw opposition from those defending executive management prerogatives or concerned about downstream fiscal/oversight implications. The limited complexity and low new-spending profile work in its favor, but Senate procedural dynamics and potential executive resistance lower overall odds.
Relative to its intended legislative type, this bill establishes clear substantive legal obligations on NIH and HHS regarding release of funds, limits on termination authority, mandatory contract clause content, and a specific regulatory revision. It provides some operational detail (responsible official, immediate release, reimbursement payment, 90-day notice), but omits definitional precision, fiscal authorization or estimate, enforcement or remedies, and a timeline for regulatory action.
Progressives emphasize protections for research continuity and guarding against political interference; conservatives emphasize restriction of agency discretion and taxpayer oversight.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize protections for research continuity and guarding against political interference; conservatives emphasize restriction of agency discretion and taxpayer oversight.
A mainstream liberal/left-leaning observer would likely view the bill positively as a protection against abrupt funding freezes or politically motivated cancellations that disrupt ongoing scientific research.
They would see it as safeguarding researchers, institutions, and projects—especially those serving public health, underserved communities, or contested topics—from administrative or political interference.
They would nonetheless look for clear protections for accountability (fraud, waste, safety) and for adequate enforcement to ensure the law actually prevents improper terminations.
A pragmatic centrist would likely be cautiously supportive of protections for active research but would want clearer guardrails for fiscal stewardship and agency flexibility.
They would appreciate preventing arbitrary interruptions to ongoing studies while insisting on well-defined grounds for termination and procedures that preserve accountability.
They would also be attentive to budgetary and legal interactions with appropriations and existing grant regulations.
A mainstream conservative would likely be skeptical of the bill as written because it restricts agency discretion and could impede management of taxpayer funds.
They would see the measure as hampering NIH’s ability to reallocate resources to higher priorities, to stop poorly performing or duplicative projects, or to act when circumstances change.
Some conservatives might support protections against blatantly political freezes but would generally prefer stronger accountability provisions and narrower constraints on agency decision-making.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is narrowly tailored and administratively focused, which helps its prospects. However, it materially constrains NIH termination authority and directs immediate release of funds for existing agreements—actions that could draw opposition from those defending executive management prerogatives or concerned about downstream fiscal/oversight implications. The limited complexity and low new-spending profile work in its favor, but Senate procedural dynamics and potential executive resistance lower overall odds.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize protections for research continuity and guarding against political interference; conservatives emphasize restriction…
On content alone, the bill is narrowly tailored and administratively focused, which helps its prospects. However, it materially constrains…
Relative to its intended legislative type, this bill establishes clear substantive legal obligations on NIH and HHS regarding release of funds, limits on termination authority, mandatory contract clause content, and a s…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.